Taifu Capital

Taifu Capital operates as a specialized life sciences venture capital firm, concentrating its efforts on providing both financial capital and strategic operational expertise to innovative companies. The firm’s core approach involves identifying and nurturing promising biotech enterprises globally, with a particular focus on early-stage innovators. Taifu Capital leverages extensive proprietary sourcing networks and cultivates diverse partnerships within the biopharmaceutical industry to support its portfolio companies.

The firm was founded in 2013, with K. Chiang serving as the Founding & Managing Partner and Wei Cheng as a Partner. K. Chiang brings over 30 years of experience in venture capital and fund management, while Wei Cheng contributes more than 20 years of expertise across biomedical research and development, business development, and investment. Their collective background in early-stage investing and the pharmaceutical sector formed the foundational insight for establishing a firm dedicated to empowering advancements in innovative biotech.

Taifu Capital primarily partners with early-stage innovators, guiding them through development with comprehensive support. The company’s long-term vision is centered on strategic global expansion into key biopharma hubs, aiming to foster innovation, capitalize on local ecosystems, and enhance cross-regional collaboration within the life sciences sector. This forward-looking approach positions Taifu Capital at the nexus of global biotech advancement.